Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adipose-derived mesenchymal stem cell secretome + transforming growth factor beta 3
- Development stage
- Unknown
- Lead developer
- Universitas Indonesia
- Modality
- Stem Cell Therapies → Cell Therapies, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal
01
Overview
This combination therapy consists of a secretome derived from adipose-derived mesenchymal stem cells (ADMSCS) and exogenous transforming growth factor beta 3 (TGF-β3). Developed by Indonesia University and produced at Dr. Cipto Mangunkusumo Hospital, it is intended for the treatment of melasma. The secretome is a bioactive medium containing growth factors, cytokines, and extracellular vesicles (including exosomes) that promote tissue regeneration and depigmentation. TGF-β3 is specifically added to enhance the depigmenting effect by inhibiting melanogenesis through the downregulation of the ERK/MITF signaling pathway. This suppression of microphthalmia-associated transcription factor (MITF) leads to reduced tyrosinase activity and melanin accumulation. Unlike TGF-β1, TGF-β3 is reported to restore skin differentiation in UV-irradiated keratinocytes without the significant risk of inducing skin fibrosis.
- Other names
- ADMSCS secretome + TGF-beta 3Concentrated secretome with addition of TGF Beta 3Concentrated secretome Injection 3 mL with addition of TGF Beta 3
Beyond the preview
Go deeper on adipose-derived mesenchymal stem cell secretome + transforming growth factor beta 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adipose-derived mesenchymal stem cell secretome + transforming growth factor beta 3.